Claudia Posadas
About Claudia Posadas
Claudia Posadas is the Senior Manager of Global Regulatory CMC Biologics at Bristol Myers Squibb, with extensive experience in biologics development and commercialization.
Company
Claudia Posadas is currently serving as the Senior Manager Global Regulatory CMC Biologics at Bristol Myers Squibb. Her role is based in Devens, MA. She has also held multiple positions at the same company, contributing significantly to its various projects and teams over the years.
Title
Claudia Posadas holds the title of Senior Manager Global Regulatory CMC Biologics. This role involves directing critical regulatory and analytical activities in compliance with cGMP and global standards, particularly in the field of biologics.
Education and Expertise
Claudia Posadas obtained her Master of Arts (M.A.) in Chemistry from Washington University in St. Louis, where she studied from 2013 to 2018. She also earned a Bachelor of Science (B.S.) in Biological and Physical Sciences from the University of Houston-Downtown, where she studied from 1997 to 2000. Her extensive educational background has provided her with a strong base in both chemistry and biology.
Background
Claudia Posadas has accumulated extensive experience in the biopharmaceutical industry. Her previous roles include Manager, Analytical CMC Strategist Scientist-Global Analytical Science & Technology, and Analytical Technical Product Lead at Bristol Myers Squibb, as well as various positions at Pfizer Global Research and Development. She started her career with roles as a Microbiologist and Lab Assistant, which laid the foundation for her expertise in biologics.
Achievements
Claudia Posadas has led regulatory submissions for multiple biological products worldwide, playing a crucial role in their commercialization and life-cycle management. She has also been involved in Health Authority Inspections and has expertise in analytical method validation and transfer. Additionally, she has successfully implemented management strategies to enhance efficiency, productivity, and compliance in biologics development.